EGFR and non-small cell lung carcinoma: One case study demonstrates complete resolution of progressive sellar disease from metastatic non-small cell lung cancer with osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, after discontinuation of carboplatin and pemetrexed due to an unfavorable side effect profile [8].